ESC 365 - Dual versus triple antithrombotic therapy, does trial design make the difference?

ESC Premium Access

Dual versus triple antithrombotic therapy, does trial design make the difference?

Session: Dual versus Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Stenting

Topic: Pharmacotherapy

Speaker: Professor R. Storey (Sheffield, GB)

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Professor Robert Storey

University of Sheffield, Sheffield (United Kingdom of Great Britain & Northern Ireland)

24 presentations

4 followers

3 more presentations in this session

A historical perspective: why we opted triple therapy for so long and what made us change our mind.

Speaker: Professor D. Angiolillo (Jacksonville, US)

Triple therapy: still an option?

Speaker: Professor K. Huber (Vienna, AT)

Dual versus triple antithrombotic therapy - The fine art of personalised medicine.

Speaker: Professor R. De Caterina (Pisa, IT)

Access the full session

Dual versus Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Stenting

Speakers: Professor R. Storey, Professor D. Angiolillo, Professor K. Huber, Professor R. De Caterina

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

novartis

Explore sponsored resources